Malottki K., Barton P., Tsourapas A., Uthman A., Liu Z., Routh K., Connock M., Jobanputra P., Moore D., Fry-Smith A., Chen Y-F. (2011), Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation., Health Technology Assessment, Vol. 15: No. 14.
Connock M., Tubeuf S., Malottki K., Uthman A., Round J., Bayliss S., Meads C., Moore D. (2010), Certolizumab pegol (CIMZIA®) for the treatment of Rheumatoid Arthritis., Health Technology Assessment., Vol. 14: Suppl. 2, 1-10.
Chen Y-F., Jowett S., Barton P., Malottki K., Hyde C., Gibbs S., et al (2009), Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation., Health Technology Assessment; Vol. 13: No.49.
Malottki K., Fry-Smith A., Moore D. (2008), Mapping the evidence base and use of neurostimulators. Report number 70, Unit of Public Health, Epidemiology and Biostatistics, University of Birmingham. ISBN: 0704427192 – 9780704427198